Pekingnology • 33 implied HN points • 29 Dec 25
- The market selloff reflects not just scientific doubt about GV-971 but major reputational and regulatory risk tied to Green Valley’s history.
- Green Valley has a long record of marketing and compliance scandals — including unlawful advertising, forged promotional materials, bribery, revoked approvals — and GV-971’s broader efficacy claims rest on limited and contested evidence.
- Key background on Green Valley’s past was largely missing from Fosun’s disclosure and much international coverage, which matters because the deal and the drug’s future still depend on regulatory approval and confirmatory clinical data.